

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Mr David Clarke                |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Managing Director              |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Mr David Clarke  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Unlisted Options to acquire Ordinary Shares at NZ\$0.39 ( A\$0.36 ) each       |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as an officer and director of Neuren Pharmaceuticals Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |  |
|-----|---|--|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 4,241,888 Options to acquire Ordinary Shares |
|-----|---|--|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Dr Douglas Wilson              |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Director                       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |     |
|----|--|-----|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | N/A |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | N/A |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | N/A |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |     |
|-----|---|-----|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | N/A |
|-----|---|-----|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Mr Peter Bailey                |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Chief Financial Officer        |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Mr Peter Bailey  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Unlisted Options to acquire Ordinary Shares at NZ\$0.39 ( A\$0.36 ) each |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as an officer of Neuren Pharmaceuticals Limited        |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |  |
|-----|---|--|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 462,197 Options to acquire Ordinary Shares |
|-----|---|--|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Mr Peter Bailey                |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Chief Financial Officer        |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |   |
|----|--|---|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Mr Peter William Bailey & Mrs. Laura Jane Bailey                  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary Shares   |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as an officer of Neuren Pharmaceuticals Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                        |
|-----|---|------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 10,000 Ordinary Shares |
|-----|---|------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Dr Peter Gluckman              |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Chief Scientific Officer       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Mr. Peter David Gluckman   |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Unlisted Options to acquire Ordinary Shares at NZ\$0.39 ( A\$0.36 ) each |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as an officer of Neuren Pharmaceuticals Limited        |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |  |
|-----|---|--|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 4,760,341 Options to acquire Ordinary Shares |
|-----|---|--|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

*Section 19T, Securities Markets Act 1988*

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Professor Peter David Gluckman |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Chief Scientific Officer       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |   |
|----|--|---|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Professor Peter David Gluckman            |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary Shares                           |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Officer of Neuren Pharmaceuticals Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                         |
|-----|---|-------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 280,297 Ordinary Shares |
|-----|---|-------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Professor Peter David Gluckman |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | EndocrinZ Founders Limited     |
| 4. | Position you hold in the issuer                | Chief Scientific Officer       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | EndocrinZ Founders Limited                             |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary Shares  |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Director and shareholder of EndocrinZ Founders Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 1,605,336 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Dr Robin Congreve              |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | N/A                            |
| 4. | Position you hold in the issuer                | Director                       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |   |
|----|--|---|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | T.A.C. Murray and Quartet Equities Limited as trustees of The Congreve Family Trust |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares   |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as a beneficiary of The Congreve Family Trust                     |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 3,704,244 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Dr Robin Congreve              |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | EndocrinZ Founders Limited     |
| 4. | Position you hold in the issuer                | Director                       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | EndocrinZ Founders Limited                             |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares  |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Director and shareholder of EndocrinZ Founders Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 1,605,336 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Dr Robin Congreve              |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | Hazardous Investments Limited  |
| 4. | Position you hold in the issuer                | Director                       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Hazardous Investments Limited  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares  |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Director of Hazardous Investments Limited and indirect shareholding held by associated interests |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 3,293,711 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                   |
|----|--|-----------------------------------|
| 1. | Name   | Dr Robin Congreve                 |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited    |
| 3. | Name of related body corporate (if applicable) | Oceania & Eastern Biotech Limited |
| 4. | Position you hold in the issuer                | Director                          |
| 5. | Date of this disclosure notice                 | 9 February 2005                   |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Oceania & Eastern Biotech Limited  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Unlisted Options to acquire Ordinary Shares at NZ\$0.39 (A\$0.36) each                               |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Director of Oceania & Eastern Biotech Limited and indirect shareholding held by associated interests |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |  |
|-----|---|--|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 1,528,892 Options to acquire Ordinary Shares |
|-----|---|--|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                   |
|----|--|-----------------------------------|
| 1. | Name   | Dr Robin Congreve                 |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited    |
| 3. | Name of related body corporate (if applicable) | Oceania & Eastern Biotech Limited |
| 4. | Position you hold in the issuer                | Director                          |
| 5. | Date of this disclosure notice                 | 9 February 2005                   |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Oceania & Eastern Biotech Limited  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares  |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Director of Oceania & Eastern Biotech Limited and indirect shareholding held by associated interests |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 2,686,926 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Dr Robin Congreve              |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | NeuronZ Limited                |
| 4. | Position you hold in the issuer                | Director                       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |                             |
|----|--|-----------------------------|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | NeuronZ Limited             |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares             |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Director of NeuronZ Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                            |
|-----|---|----------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 12,345,898 Ordinary Shares |
|-----|---|----------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |                                |
|----|--|--------------------------------|
| 1. | Name   | Mr Trevor Donald Scott         |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited |
| 3. | Name of related body corporate (if applicable) | Centralo Limited               |
| 4. | Position you hold in the issuer                | Director                       |
| 5. | Date of this disclosure notice                 | 9 February 2005                |

### C. Nature of relevant interest

|    |  |   |
|----|--|---|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Centralo Limited                                  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares                                   |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as director of Centralo Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                         |
|-----|---|-------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 991,125 Ordinary Shares |
|-----|---|-------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |  |
|----|--|--|
| 1. | Name   | Mr Trevor Donald Scott                   |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited           |
| 3. | Name of related body corporate (if applicable) | New Zealand Seed Fund Management Limited |
| 4. | Position you hold in the issuer                | Director                                 |
| 5. | Date of this disclosure notice                 | 9 February 2005                          |

### C. Nature of relevant interest

|    |  |   |
|----|--|---|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | New Zealand Seed Fund Management Limited                                      |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares   |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as director of the New Zealand Seed Fund Management Limited |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                            |
|-----|---|----------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 11,441,670 Ordinary Shares |
|-----|---|----------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |  |
|----|--|--|
| 1. | Name   | Mr Tom Amos  |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited   |
| 3. | Name of related body corporate (if applicable) | Perpetual Trustee Company (Canberra) Limited ATF – Macquarie Technology Fund 1 B |
| 4. | Position you hold in the issuer                | Director   |
| 5. | Date of this disclosure notice                 | 9 February 2005  |

### C. Nature of relevant interest

|    |  |   |
|----|--|---|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Perpetual Trustee Company (Canberra) Limited ATF – Macquarie Technology Fund 1 B  |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares   |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as a representative of Perpetual Trustee Company (Canberra) Limited ATF – Macquarie Technology Fund 1 B |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 4,812,059 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|

## Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

### A. Disclosure obligation (tick box to note which disclosure obligation applies)

|                                     |   |                          |   |
|-------------------------------------|---|--------------------------|---|
| <input checked="" type="checkbox"/> | Initial disclosure (complete Parts A, B, C, D, F, and G of this notice) | <input type="checkbox"/> | Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice) |
|-------------------------------------|---|--------------------------|---|

### B. Preliminary

|    |  |  |
|----|--|--|
| 1. | Name   | Mr Tom Amos  |
| 2. | Name of issuer                                 | Neuren Pharmaceuticals Limited   |
| 3. | Name of related body corporate (if applicable) | Perpetual Trustee Company Limited<br>ATF – Macquarie Technology Fund 1 A |
| 4. | Position you hold in the issuer                | Director   |
| 5. | Date of this disclosure notice                 | 9 February 2005  |

### C. Nature of relevant interest

|    |  |  |
|----|--|--|
| 6. | Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b)) | Perpetual Trustee Company Limited<br>ATF – Macquarie Technology Fund 1 A   |
| 7. | Class and type of security (as required by regulation 6B or regulation 8)                      | Ordinary shares  |
| 8. | Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))   | Relevant interest as a representative of<br>Perpetual Trustee Company Limited<br>ATF – Macquarie Technology Fund 1 A |

### D. Date (for initial disclosure)

|    |  |                 |
|----|--|-----------------|
| 9. | Date of disclosure obligation (as required by regulation 6C) | 3 February 2005 |
|----|--|-----------------|

### E. Transaction (for ongoing disclosure)

|     |   |  |
|-----|---|--|
| 10. | Date of last disclosure (as required by regulation 13)                  |  |
| 11. | Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)  |  |
| 12. | Number of transactions (as required by regulation 12(2), if applicable) |  |
| 13. | Nature or type of transaction (as required by regulation 11(1)(a))      |  |
| 14. | Consideration (as required by regulation 10)                            |  |

|     |  |  |
|-----|--|--|
| 15. | Number of securities held prior, set out by class and type (as required by regulation 8)     |  |
| 16. | Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b)) |  |

**F. Extent of relevant interest**

|     |   |                           |
|-----|---|---------------------------|
| 17. | Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8) | 4,812,059 Ordinary Shares |
|-----|---|---------------------------|

**G. Signature**

|     |  |  |
|-----|--|--|
| 18. | Signature (as required by regulation 14) |  |
|-----|--|--|